Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switch Paradigm Change Sees Long Road, Breeds Questions

This article was originally published in The Tan Sheet

Executive Summary

Industry has opposed establishing an intermediate class of drugs between Rx and OTC, and FDA has held it does not have authority to require firms to allow products to be approved for behind-the-counter access or some other alternative distribution. But the creation of some form of third route to access appears likely.

Advertisement

Related Content

CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes
CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes
Rescue Medicine Switch Concept Draws Criticism
Rescue Medicine Switch Concept Draws Criticism
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board
FDA's ONP Reorganization Challenges Industry To Prioritize OTCs
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel